Search Results
Nov 05, 2025, 16:07 ET Precision Biologics to Reveal Preclinical Efficacy of Novel Tumor-Specific ADC against multiple human cancer types at SITC 2025
mice: The efficacy of the ADC PB-vcMMAE-5 was assessed in OV-90 (ovarian) subcutaneous xenograft model established in NOD-SCID mice. The ADC PB-vcMMAE-5 was administered intravenously at doses 1, 3, 6 or 9 mg/kg, once per week for five weeks. On day 31 from the first ADC infusion, most alive mice
More news about: Precision Biologics
Nov 05, 2025, 12:57 ET Piramal Pharma Limited Announces Results for Q2 and H1 FY26
- Recently increasing RFPs/RFIs- especially for our onshore manufacturing facilities and differentiated capabilities like ADC, Sterile fill-finish, and on-patent commercial manufacturing, where we have made significant investments in capabilities and capacities.
More news about: Piramal Pharma Limited
Nov 05, 2025, 08:00 ET BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC
helps Lepu Biopharma win China's marketing approval for EGFR-targeted ADC treating recurrent or metastatic nasopharyngeal carcinoma This Becotatug Vedotin injection approval is BioDlink's first commercial ADC manufacturing initiative worldwide, validating its complex biologics
More news about: BioDlink Biopharm Co., Ltd.
Nov 04, 2025, 07:30 ET Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications
(Tagrisso®, AstraZeneca) and EGFR tyrosine kinase inhibitor (TKI), second-line Dato-DXd (Datroway®, AstraZeneca/Daiichi Sankyo) a Trop-2 ADC, and third-line amivantamab (Rybrevant®, Johnson & Johnson) an EGFR-cMET bispecific. Combined 2024 sales of these agents exceeded $7B.
More news about: Actinium Pharmaceuticals, Inc.
Nov 04, 2025, 06:20 ET Next-Generation Multiple Myeloma Therapies Market to Reach USD 37.07 Billion by 2033, Driven by Accelerated Immunotherapy Approvals and Precision Medicine Advances - DataM Intelligence
GSK plc reported new data for Blenrep (belantamab mafodotin) with a median duration of response of 12.9 months, reinforcing ADC efficacy. Amgen announced plans to launch an oral proteasome inhibitor by 2026, targeting maintenance
More news about: DataM Intelligence 4 Market Research LLP
Nov 04, 2025, 06:00 ET IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
(OptimUM-01) evaluating the darovasertib/crizotinib combination in 1L mUM Phase 1 data reported in SCLC for IDE849 (DLL3 TOP1i ADC) at the World Conference on Lung Cancer. Preliminary evidence of clinical efficacy was also observed in NETs patients, including Partial Responses by
More news about: IDEAYA Biosciences, Inc.
Nov 03, 2025, 08:30 ET Clinical Signals and Strategic Shifts: Insights That Shape Oncology Drug Development, Upcoming Webinar Hosted by Xtalks
immuno-oncology continues to evolve, which emerging therapies are poised to reshape the standard of care? Is the next wave of antibody-drug conjugate (ADC) innovation — including integration with bispecific and tri-specific platforms — delivering on its promise to transform precision oncology, or are we
More news about: Xtalks
Nov 03, 2025, 08:00 ET Precision Medicine Group Launches Institute@Precision, a Collaborative Forum for Biopharma Innovation
anniversary of the first ADC approval, 15 ADCs have been approved1 and more than 200 are being evaluated in clinical trials.2 "With ADCs, we spotlight a remarkable example of progress and persistence. Over the past 25 years, pioneers in ADC science have overcome
More news about: Precision Medicine Group
Nov 03, 2025, 07:15 ET ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025
for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early-stage PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment
More news about: ADC Therapeutics SA
Oct 31, 2025, 07:49 ET AbbVie Reports Third-Quarter 2025 Financial Results
submission of a new Biologics License Application (BLA) to the FDA for approval of pivekimab sunirine (PVEK), an investigational antibody-drug conjugate (ADC), for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). The submission is based on data from the Phase 1/2 CADENZA trial, a global study
More news about: AbbVie
Oct 31, 2025, 03:00 ET Mycenax y RIN firman un acuerdo de licencia para impulsar el desarrollo de ADC
que permite el desarrollo de ADC avanzados. En concreto, el ligador VLK facilita la citotoxicidad mediante dos mecanismos: la acción en el microambiente tumoral y una mejor internalización del ADC. El acuerdo refuerza la capacidad de Mycenax para ofrecer soluciones de ADC diferenciadas a sus socios farmacéuticos
More news about: Mycenax Biotech Inc.
Oct 31, 2025, 03:00 ET Mycenax and RIN Sign License Agreement to Advance ADC Development Using RIN's Proprietary Linker Technology
facilitates cytotoxicity through two mechanisms: action within the tumor microenvironment and enhanced ADC internalization. The agreement strengthens Mycenax's capability to deliver differentiated ADC solutions for global pharmaceutical partners. "We are thrilled to finalize this
More news about: Mycenax Biotech Inc.
Oct 31, 2025, 03:00 ET Mycenax und RIN unterzeichnen Lizenzvereinbarung zur Förderung der ADC-Entwicklung unter Verwendung der proprietären Linker-Technologie von RIN
Zytotoxizität durch zwei Mechanismen: die Wirkung innerhalb der Tumormikroumgebung und eine verbesserte ADC-Internalisierung. Die Vereinbarung stärkt die Fähigkeit von Mycenax, differenzierte ADC-Lösungen für globale Pharmapartner bereitzustellen. „Wir freuen uns sehr über den
More news about: Mycenax Biotech Inc.
Oct 31, 2025, 03:00 ET Mycenax et RIN signent un accord de licence pour faire progresser le développement d'ADC à l'aide de la technologie de liaison exclusive de RIN
de Mycenax à fournir des solutions ADC différenciées à ses partenaires pharmaceutiques mondiaux. « Nous sommes ravis de finaliser cet accord avec l'Institut RIN, qui marque une étape importante dans notre mission de fournir des solutions ADC innovantes et compétitives », a déclaré
More news about: Mycenax Biotech Inc.
Oct 30, 2025, 23:46 ET Piramal Pharma Solutions formalizza la partnership stretta con IntoCell espandendo la propria piattaforma Payload-Linker e le capacità di sviluppo di bioconiugati
anticorpo-farmaco (ADC), Piramal rafforza il proprio vantaggio competitivo nel mercato dei bioconiugati. Questo accordo supporta ADCelerate™, l'approccio rapido di Piramal allo sviluppo e alla produzione di ADC.
More news about: Piramal Pharma Solutions
Oct 30, 2025, 19:00 ET Piramal Pharma Solutions formalisiert Partnerschaft mit IntoCell und erweitert seine Payload-Linker-Plattform und Biokonjugat-Kapazitäten
Herstellung von ADC stärkt Piramal seine Wettbewerbsposition auf dem Markt für Biokonjugate. Diese Vereinbarung unterstützt ADCelerate™, Piramals schnellen Ansatz für die Entwicklung und Herstellung von ADC.
More news about: Piramal Pharma Solutions
Oct 30, 2025, 18:56 ET Piramal Pharma Solutions officialise son partenariat avec IntoCell, élargissant ainsi sa plateforme de payload-linker et ses capacités en matière de bioconjugués
coréenne de premier plan spécialisée dans les technologies innovantes de liaison et de plateforme de payload pour les conjugués anticorps-médicaments (ADC). En vertu de cet accord non exclusif et non contraignant, IntoCell explorera les possibilités de licence pour ses technologies propriétaires de liaison
More news about: Piramal Pharma Solutions
Oct 30, 2025, 07:36 ET Piramal Pharma Solutions formaliza su asociación con IntoCell
anticuerpo-fármaco (ADC), Piramal refuerza su ventaja competitiva en el mercado de bioconjugados. Este acuerdo respalda ADCelerate™, la metodología de Piramal para el desarrollo y la fabricación ágiles de ADC.
More news about: Piramal Pharma Solutions
Oct 30, 2025, 01:21 ET Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities
formidable 20-year experience in ADC development and manufacture, Piramal strengthens its competitive edge in the bioconjugate market. This agreement supports ADCelerate™, Piramal's rapid approach to ADC development and manufacture.
More news about: Piramal Pharma Solutions
Oct 30, 2025, 01:15 ET Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities
formidable 20-year experience in ADC development and manufacture, Piramal strengthens its competitive edge in the bioconjugate market. This agreement supports ADCelerate™, Piramal's rapid approach to ADC development and manufacture.
More news about: Piramal Pharma Solutions
Oct 29, 2025, 08:33 ET GlycoNex Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis
advancing a portfolio of antibody-drug conjugates (ADCs) that precisely attack cancer cells while sparing healthy tissue, including GNX1021, its novel ADC that targets branched Lewis B/Y (bLeB/Y). GlycoNex is headquartered in New Taipei City, Taiwan. For more information, visit
More news about: GlycoNex, Inc.
Oct 29, 2025, 05:49 ET Thousand Oaks Biologics Showcases Integrated ADC CRDMO Solutions & Media Innovation for Industrialization at CPHI Frankfurt 2025
Integrated ADC CMC Technology Platform: Driven by AI, this platform features a co-located production layout for naked antibody, ADC drug substance, and ADC drug product within a single facility, significantly streamlining development and tech transfer. The Shanghai ADC production site, which
More news about: Thousand Oaks Biologics
Oct 28, 2025, 19:00 ET Pinetree Therapeutics Raises $47 Million in Oversubscribed Series B to Advance Next-Generation Protein Degraders in Oncology
extracellular proteins, offering a differentiated mechanism of action and durable therapeutic benefit. Pinetree is also advancing trispecific degraders and ADC-integrated platforms, and has entered strategic partnerships, including a licensing agreement with AstraZeneca. [
More news about: PineTree Therapeutics
Oct 28, 2025, 10:47 ET Tsingke Biotech Showcased AI-Powered Biomanufacturing Solutions at 2025 Festival of Biologics
High-throughput gene synthesis and modified primers for epitope mapping Chemically modified oligos and conjugation modules for ADC/PROTAC/AOC R&D Optimized nucleic acid purification and LNP encapsulation for process translation
More news about: Beijing Tsingke Biotech Co., Ltd.
Oct 28, 2025, 10:47 ET Tsingke Biotech Showcased AI-Powered Biomanufacturing Solutions at 2025 Festival of Biologics
High-throughput gene synthesis and modified primers for epitope mapping Chemically modified oligos and conjugation modules for ADC/PROTAC/AOC R&D Optimized nucleic acid purification and LNP encapsulation for process translation
More news about: Beijing Tsingke Biotech Co., Ltd.